---
title: "昆药集团股份有限公司 (600422.SH)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/600422.SH.md"
symbol: "600422.SH"
name: "昆药集团股份有限公司"
industry: "制药"
---

# 昆药集团股份有限公司 (600422.SH)

| Item | Detail |
|------|--------|
| Industry | 制药 |
| Location | 沪深市场 |
| Website | [www.kpc.com.cn](https://www.kpc.com.cn) |

## Company Profile

公司成立于 1951 年 3 月，2000 年 12 月在上海证券交易所上市。公司拥有深厚的专业制药经验。依托云南丰富的植物资源，公司先后开发了青蒿、三七、天麻三大系列及特色中药、民族药等 40 多个具有国内外先进水平的天然药物新产品公司所处行业为医药制造业，业务领域覆盖医药全产业链，核心业务涵盖药物研发、生产及销售、医药流通及大健康产业等领域。公司核心产品包括昆药血塞通系列、蒿甲醚系列，华润圣火理洫王血塞通软胶囊，昆中药参苓健脾胃颗粒、舒肝颗粒、香砂平胃颗粒，贝克诺顿阿法骨化醇软胶囊、玻璃酸钠注射液等。公司入选国家工业和信息化部评定的 “国家技术创新示范企业”、中国医药企业管理协会等联合评选...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-20T04:30:09.000Z

**Overall: C (0.57)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 106 / 222 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -21.72% |  |
| Net Profit YoY | -46.00% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 1.75 |  |
| Dividend Ratio | 2.44% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 9.31B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 6.58B |  |


**Multi Score**: C

#### Profit Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 6.63% | C |
| Profit Margin | 5.32% | C |
| Gross Margin | 6.82% | E |

#### Growth Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -21.72% | E |
| Net Profit YoY | -46.00% | D |
| Total Assets YoY | 0.00% | C |
| Net Assets YoY | 1.62% | C |

#### Cash Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | 1879.36% | A |
| OCF YoY | -21.72% | E |

#### Operating Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.00 | E |

#### Debt Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 0.00% | A |


```chart-data:radar
{
  "title": "Longbridge Financial Score - 昆药集团股份有限公司",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "6.63%",
          "rating": "C"
        },
        {
          "name": "Profit Margin",
          "value": "5.32%",
          "rating": "C"
        },
        {
          "name": "Gross Margin",
          "value": "6.82%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "D",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-21.72%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-46.00%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "0.00%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "1.62%",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "C",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "1879.36%",
          "rating": "A"
        },
        {
          "name": "OCF YoY",
          "value": "-21.72%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "E",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.00",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "A",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "0.00%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | 艾力斯 (SH.688578) | A | A | B | A | B | A |
| 02 | 兴齐眼药 (SZ.300573) | A | A | A | B | B | A |
| 03 | 恒瑞医药 (SH.600276) | A | B | C | A | B | B |
| 04 | 云南白药 (SZ.000538) | B | C | B | B | C | B |
| 05 | 信立泰 (SZ.002294) | B | B | C | A | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 19.69 | 34/222 | 20.78 | 19.82 | 18.51 |
| PB | 1.75 | 57/222 | 2.27 | 2.05 | 1.86 |
| PS (TTM) | 1.27 | 12/222 | 1.50 | 1.37 | 1.33 |
| Dividend Yield | 2.44% | 36/222 | 2.31% | 2.08% | 1.25% |

## Institutional View

### Analyst Rating Distribution

> As of 2025-11-10T16:00:00.000Z

Total Analysts: **7**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 5 | 71% |
| Overweight | 1 | 14% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 12.30 |
| Highest Target | 21.36 |
| Lowest Target | 21.34 |

## References

- [Company Overview](https://longbridge.com/en/quote/600422.SH/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/600422.SH/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/600422.SH/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.